← SynDRA
SELINEXOR
SynDRA canonical compound SYN0038239 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | XPO1 |
|---|
| Mechanism of action | exportin antagonist |
|---|
| Indication | multiple myeloma |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
- XPO1 INHIBITOR
- Exportin-1 inhibitor
- exportin antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PTGS2
- PTGS1
- ACHE
- NR3C1
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- KDR
- MAOA
- MC3R
- MLNR
- NR1I2
- OPRM1
- OPRD1
- ADORA1
- PDE3A
- PDE4A
- PDE4D
- PGR
- PPARG
- SCN5A
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- HRH3
- HRH1
- HDAC6
- GHSR
- ADORA2A
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLAB
- IFNB1
- IFNG
- KSYK
- NSD2
- SYK
Drug classes
- Nuclear Export Inhibitor
- Nuclear Export Inhibitors
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- XPOVIO
- Xpovio
- xpovio
- KPT-330
- Nexpovio
- KPT-330(Selinexor)
- KPT330;Selinexor
- 31TZ62FO8F
- CHEMBL3545185
- SCHEMBL14678327
- Selinexor (KPT-330)
- Selinexor [USAN:INN]
- Tube706
- UNII-31TZ62FO8F
- KPT 330
- Selinexor free base
- Selinexor [INN]
- Xpovio (TN)
- SELINEXOR [MI]
- Selinexor (USAN/INN)
- SELINEXOR [USAN]
- SELINEXOR [WHO-DD]
- SELINEXOR [ORANGE BOOK]
- GTPL10036
- EX-A870
- DTXSID801026013
- BDBM50527778
- MFCD27987944
- NSC780203
- NSC781780
- ZINC96170454
- CCG-269161
- DB11942
- NSC-780203
- NSC-781780
- NCGC00386310-01
- NCGC00386310-03
- AC-33645
Reported adverse events
- Abdominal pain
- Cataract
- Cough
- Dehydration
- Dizziness
- Epistaxis
- Fatigue
- Headache
- Hypotension
- Infection
- Insomnia
- Leukopenia
Look up SELINEXOR in the interactive SynDRA portal →